All In Biotech

Drug Trial Radar · NCT02260986

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

740

Actual

Start

Sep 2014

Primary completion

Aug 2015

Study completion Oct 2016

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Oct 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

    Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

  • Placebo (for Dupilumab)Drug

    Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

  • Topical Corticosteroid (TCS)Other

    All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16Time frame: Baseline to Week 16

Locations

148 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Encinitas, California

  • Site not named

    Oceanside, California

  • Site not named

    Palmdale, California

  • Site not named

    San Diego, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Edgewater, Florida

  • Site not named

    Lake Worth, Florida

  • Site not named

    Miami Lakes, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    West Dundee, Illinois

  • Site not named

    Carmel, Indiana

  • Site not named

    New Albany, Indiana

  • Site not named

    Rockville, Maryland

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Bay City, Michigan

  • Site not named

    Edina, Minnesota

  • Site not named

    Fridley, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Henderson, Nevada

  • Site not named

    Verona, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Corning, New York

  • Site not named

    New York, New York

  • Site not named

    Smithtown, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Norman, Oklahoma

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Lake Oswego, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Exton, Pennsylvania

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.